1.Clinical implications of idiopathic pulmonary fibrosis and lung cancer
Precision and Future Medicine 2025;9(1):35-42
Idiopathic pulmonary fibrosis (IPF) is characterized by chronic progressive fibrosis of the lungs of unknown etiology. The prognosis of IPF is poor, with a median survival of 3 to 5 years. Lung cancer is one of the most frequently associated comorbidities of IPF, often resulting in grave outcomes. Patients with IPF have a higher risk for lung cancer than the general population. Lung cancer frequently develops in older male IPF patients with smoking history. Squamous cell carcinoma is the most common histological type, followed by adenocarcinoma. Such cancers typically develop abutting or within fibrosis. One of the major obstacles in making therapeutic decisions for these patients is the complications after treatment and subsequent poor prognosis. Numerous studies have reported post-treatment complications, such as acute exacerbation of IPF, pneumonia, and persistent air leakage, and their impact on survival. Higher mortality rates have consistently been reported among patients diagnosed with both IPF and lung cancer compared to those with either IPF or lung cancer alone. Thorough risk assessment for complications, selection of appropriate therapeutic modality, and use of antifibrotic agents, such as pirfenidone or nintedanib, may help prevent complications and improve survival. Nevertheless, further research is necessary to establish optimal treatment strategies for patients diagnosed with IPF and lung cancer.
2.COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea:A Nationwide Multicenter Survey
Hongseok YOO ; Song Yee KIM ; Moo Suk PARK ; Sung Hwan JEONG ; Sung-Woo PARK ; Hong Lyeol LEE ; Hyun-Kyung LEE ; Sei-Hoon YANG ; Yangjin JEGAL ; Jung-Wan YOO ; Jongmin LEE ; Hyung Koo KANG ; Sun Mi CHOI ; Jimyung PARK ; Young Whan KIM ; Jin Woo SONG ; Joo Hun PARK ; Won-Il CHOI ; Hye Sook CHOI ; Chul PARK ; Jeong-Woong PARK ; Man Pyo CHUNG
Journal of Korean Medical Science 2023;38(14):e106-
Background:
Recent reports have suggested that pneumonitis is a rare complication following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).However, its clinical features and outcomes are not well known. The aim of this study was to identify the clinical characteristics and outcomes of patients with vaccine-associated pneumonitis following vaccination against SARS-CoV-2.
Methods:
In this nationwide multicenter survey study, questionnaires were distributed to pulmonary physicians in referral hospitals. They were asked to report cases of development or exacerbation of interstitial lung disease (ILD) associated with the coronavirus disease 2019 vaccine. Vaccine-associated pneumonitis was defined as new pulmonary infiltrates documented on chest computed tomography within 4 weeks of vaccination and exclusion of other possible etiologies.
Results:
From the survey, 49 cases of vaccine-associated pneumonitis were identified between February 27 and October 30, 2021. After multidisciplinary discussion, 46 cases were analyzed. The median age was 66 years and 28 (61%) were male. The median interval between vaccination and respiratory symptoms was 5 days. There were 20 (43%), 17 (37%), and nine (19%) patients with newly identified pneumonitis, exacerbation of pre-diagnosed ILD, and undetermined pre-existing ILD, respectively. The administered vaccines were BNT162b2 and ChAdOx1 nCov-19/AZD1222 each in 21 patients followed by mRNA-1273 in three, and Ad26.COV2.S in one patient. Except for five patients with mild disease, 41 (89%) patients were treated with corticosteroid. Significant improvement was observed in 26 (57%) patients including four patients who did not receive treatment. However, ILD aggravated in 9 (20%) patients despite treatment. Mortality was observed in eight (17%) patients.
Conclusion
These results suggest pneumonitis as a potentially significant safety concern for vaccines against SARS-CoV-2. Clinical awareness and patient education are necessary for early recognition and prompt management. Additional research is warranted to identify the epidemiology and characterize the pathophysiology of vaccine-associated pneumonitis.
3.Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 1. Introduction
Sung Woo PARK ; Ae Rin BAEK ; Hong Lyeol LEE ; Sung Whan JEONG ; Sei Hoon YANG ; Yong Hyun KIM ; Man Pyo CHUNG ;
Tuberculosis and Respiratory Diseases 2019;82(4):269-276
Idiopathic interstitial pneumonia (IIP) is a histologically identifiable pulmonary disease without a known cause that usually infiltrates the lung interstitium. IIP is largely classified into idiopathic pulmonary fibrosis, idiopathic non-specific interstitial pneumonia, respiratory bronchiolitis-interstitial lung disease (ILD), cryptogenic organizing pneumonia, desquamative interstitial pneumonia, and acute interstitial pneumonia. Each of these diseases has a different prognosis and requires specific treatment, and a multidisciplinary approach that combines chest high-resolution computed tomography (HRCT), histological findings, and clinical findings is necessary for their diagnosis. Diagnosis of IIP is made based on clinical presentation, chest HRCT findings, results of pulmonary function tests, and histological findings. For histological diagnosis, video-assisted thoracoscopic biopsy and transbronchial lung biopsy are used. In order to identify ILD associated with connective tissue disease, autoimmune antibody tests may also be necessary. Many biomarkers associated with disease prognosis have been recently discovered, and future research on their clinical significance is necessary. The diagnosis of ILD is difficult because patterns of ILD are both complicated and variable. Therefore, as with other diseases, accurate history taking and meticulous physical examination are crucial.
Biomarkers
;
Biopsy
;
Classification
;
Connective Tissue Diseases
;
Cryptogenic Organizing Pneumonia
;
Diagnosis
;
Idiopathic Interstitial Pneumonias
;
Idiopathic Pulmonary Fibrosis
;
Lung
;
Lung Diseases
;
Lung Diseases, Interstitial
;
Physical Examination
;
Prognosis
;
Respiratory Function Tests
;
Thorax
4.A Rare Case of Adenosquamous Carcinoma Arising in the Background of IgG4-Related Lung Disease
Sangjoon CHOI ; Sujin PARK ; Man Pyo CHUNG ; Tae Sung KIM ; Jong Ho CHO ; Joungho HAN
Journal of Pathology and Translational Medicine 2019;53(3):188-191
IgG4-related disease is a systemic inflammatory disease and is known as IgG4-related lung disease (IgG4-RLD) when it involves the respiratory system. Primary lung cancer arising from a background of IgG4-RLD is very rare. Herein, we report a case of adenosquamous carcinoma arising from the background of IgG4-RLD and presenting as an interstitial lung disease pattern. A 66-year-old man underwent lobectomy under the impression of primary lung cancer. Grossly, the mass was ill-defined and gray-tan colored, and the background lung was fibrotic. Microscopically, tumor cells showed both squamous and glandular differentiation. Dense lymphoplasmacytic infiltration with fibrosis and obliterative phlebitis were seen in the background lung. IgG4 immunohistochemical stain showed diffuse positivity in infiltrating plasma cells. Primary lung adenosquamous carcinoma has not been reported in a background of IgG4-RLD. Due to the rarity of IgG4-RLD, physicians must follow patients with IgG4-RLD over long periods of time to accurately predict the risk of lung cancer.
Aged
;
Carcinoma, Adenosquamous
;
Fibrosis
;
Humans
;
Immunoglobulin G
;
Lung Diseases
;
Lung Diseases, Interstitial
;
Lung Neoplasms
;
Lung
;
Phlebitis
;
Plasma Cells
;
Respiratory System
5.Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 1. Introduction
Sung Woo PARK ; Ae Rin BAEK ; Hong Lyeol LEE ; Sung Whan JEONG ; Sei Hoon YANG ; Yong Hyun KIM ; Man Pyo CHUNG ;
Tuberculosis and Respiratory Diseases 2019;82(4):269-276
Idiopathic interstitial pneumonia (IIP) is a histologically identifiable pulmonary disease without a known cause that usually infiltrates the lung interstitium. IIP is largely classified into idiopathic pulmonary fibrosis, idiopathic non-specific interstitial pneumonia, respiratory bronchiolitis-interstitial lung disease (ILD), cryptogenic organizing pneumonia, desquamative interstitial pneumonia, and acute interstitial pneumonia. Each of these diseases has a different prognosis and requires specific treatment, and a multidisciplinary approach that combines chest high-resolution computed tomography (HRCT), histological findings, and clinical findings is necessary for their diagnosis. Diagnosis of IIP is made based on clinical presentation, chest HRCT findings, results of pulmonary function tests, and histological findings. For histological diagnosis, video-assisted thoracoscopic biopsy and transbronchial lung biopsy are used. In order to identify ILD associated with connective tissue disease, autoimmune antibody tests may also be necessary. Many biomarkers associated with disease prognosis have been recently discovered, and future research on their clinical significance is necessary. The diagnosis of ILD is difficult because patterns of ILD are both complicated and variable. Therefore, as with other diseases, accurate history taking and meticulous physical examination are crucial.
6.Successful Treatment with Empirical Erlotinib in a Patient with Respiratory Failure Caused by Extensive Lung Adenocarcinoma.
Suk Hyeon JEONG ; Sang Won UM ; Hyun LEE ; Kyeongman JEON ; Kyung Jong LEE ; Gee Young SUH ; Man Pyo CHUNG ; Hojoong KIM ; O Jung KWON ; Yoon La CHOI
Korean Journal of Critical Care Medicine 2016;31(1):44-48
We herein describe a 70-year-old woman who presented with respiratory failure due to extensive lung adenocarcinoma. Despite advanced disease, care in the intensive care unit with ventilator support was performed because she was a newly diagnosed patient and was considered to have the potential to recover after cancer treatment. Because prompt control of the cancer was needed to treat the respiratory failure, empirical treatment with an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor was initiated before confirmation of EGFR-mutant adenocarcinoma, and the patient was successfully treated. Later, EGFR-mutant adenocarcinoma was confirmed.
Adenocarcinoma*
;
Aged
;
Female
;
Humans
;
Intensive Care Units
;
Lung*
;
Protein-Tyrosine Kinases
;
Receptor, Epidermal Growth Factor
;
Respiration, Artificial
;
Respiratory Insufficiency*
;
Ventilators, Mechanical
;
Erlotinib Hydrochloride
7.Successful Treatment with Empirical Erlotinib in a Patient with Respiratory Failure Caused by Extensive Lung Adenocarcinoma
Suk Hyeon JEONG ; Sang Won UM ; Hyun LEE ; Kyeongman JEON ; Kyung Jong LEE ; Gee Young SUH ; Man Pyo CHUNG ; Hojoong KIM ; O Jung KWON ; Yoon La CHOI
The Korean Journal of Critical Care Medicine 2016;31(1):44-48
We herein describe a 70-year-old woman who presented with respiratory failure due to extensive lung adenocarcinoma. Despite advanced disease, care in the intensive care unit with ventilator support was performed because she was a newly diagnosed patient and was considered to have the potential to recover after cancer treatment. Because prompt control of the cancer was needed to treat the respiratory failure, empirical treatment with an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor was initiated before confirmation of EGFR-mutant adenocarcinoma, and the patient was successfully treated. Later, EGFR-mutant adenocarcinoma was confirmed.
Adenocarcinoma
;
Aged
;
Female
;
Humans
;
Intensive Care Units
;
Lung
;
Protein-Tyrosine Kinases
;
Receptor, Epidermal Growth Factor
;
Respiration, Artificial
;
Respiratory Insufficiency
;
Ventilators, Mechanical
;
Erlotinib Hydrochloride
8.Significance of Myositis Autoantibody in Patients with Idiopathic Interstitial Lung Disease.
Ju Sun SONG ; Jiwon HWANG ; Hoon Suk CHA ; Byeong Ho JEONG ; Gee Young SUH ; Man Pyo CHUNG ; Eun Suk KANG
Yonsei Medical Journal 2015;56(3):676-683
PURPOSE: Some patients with interstitial lung disease (ILD) related to connective tissue disease (CTD) have a delayed diagnosis of the underlying CTD when the ILD is categorized as idiopathic. In this study, we evaluated the frequency of myositis autoantibodies in patients diagnosed with idiopathic ILD and investigated the clinical significance stemming from the presence of the antibodies. MATERIALS AND METHODS: A total 32 patients diagnosed with idiopathic ILD were enrolled in this study. We analyzed a panel of 11 myositis autoantibody specificities in the patients using a line blot immunoassay. Then, we divided them into myositis autoantibody-positive and -negative groups and compared the clinical features and laboratory data between the two groups. RESULTS: Of the 32 idiopathic ILD patients, 12 patients had myositis autoantibodies encompassing 9 specificities, except for anti-Mi-2 and anti-PM-Scl 100 (12/32, 38%). Anti-synthetase autoantibodies including Jo-1, EJ, OJ, PL-7, and PL-12 were present in 7 patients (7/32, 22%). The group with myositis autoantibodies presented more frequently with the symptom of mechanic's hand and showed abnormal pulmonary function test results with low forced vital capacity, diffusing capacity for carbon monoxide, total lung capacity, and high lactate dehydrogenase values in blood when compared with the group without myositis antibodies. CONCLUSION: We strongly suggest that patients undergo an evaluation of myositis autoantibodies, if they are diagnosed with idiopathic ILD in the presence of clinical characteristics including mechanic's hand, arthralgia, and autoantibodies which are insufficient to make a diagnosis of a specific CTD category.
Aged
;
Autoantibodies/*blood/immunology
;
Female
;
Humans
;
Lung Diseases, Interstitial/*diagnosis/immunology/physiopathology
;
Male
;
Middle Aged
;
Myositis/*immunology/physiopathology
;
Respiratory Function Tests
9.Changes in the Flow-Volume Curve According to the Degree of Stenosis in Patients With Unilateral Main Bronchial Stenosis.
Yousang KO ; Jung Geun YOO ; Chin A YI ; Kyung Soo LEE ; Kyeongman JEON ; Sang Won UM ; Won Jung KOH ; Gee Young SUH ; Man Pyo CHUNG ; O Jung KWON ; Hojoong KIM
Clinical and Experimental Otorhinolaryngology 2015;8(2):161-166
OBJECTIVES: The shape of the flow-volume (F-V) curve is known to change to showing a prominent plateau as stenosis progresses in patients with tracheal stenosis. However, no study has evaluated changes in the F-V curve according to the degree of bronchial stenosis in patients with unilateral main bronchial stenosis. METHODS: We performed an analysis of F-V curves in 29 patients with unilateral bronchial stenosis with the aid of a graphic digitizer between January 2005 and December 2011. RESULTS: The primary diseases causing unilateral main bronchial stenosis were endobronchial tuberculosis (86%), followed by benign bronchial tumor (10%), and carcinoid (3%). All unilateral main bronchial stenoses were classified into one of five grades (I, < or =25%; II, 26%-50%; III, 51%-75%; IV, 76%-90%; V, >90% to near-complete obstruction without ipsilateral lung collapse). A monophasic F-V curve was observed in patients with grade I stenosis and biphasic curves were observed for grade II-IV stenosis. Both monophasic (81%) and biphasic shapes (18%) were observed in grade V stenosis. After standardization of the biphasic shape of the F-V curve, the breakpoints of the biphasic curve moved in the direction of high volume (x-axis) and low flow (y-axis) according to the progression of stenosis. CONCLUSION: In unilateral bronchial stenosis, a biphasic F-V curve appeared when bronchial stenosis was >25% and disappeared when obstruction was near complete. In addition, the breakpoint moved in the direction of high volume and low flow with the progression of stenosis.
Bronchi
;
Carcinoid Tumor
;
Constriction, Pathologic*
;
Humans
;
Lung
;
Maximal Expiratory Flow-Volume Curves
;
Spirometry
;
Tracheal Stenosis
;
Tuberculosis
10.Prevalence and Correlates of DSM-IV Mental Disorders in South Korean Adults: The Korean Epidemiologic Catchment Area Study 2011.
Maeng Je CHO ; Su Jeong SEONG ; Jee Eun PARK ; In Won CHUNG ; Young Moon LEE ; Ahn BAE ; Joon Ho AHN ; Dong Woo LEE ; Jae Nam BAE ; Seong Jin CHO ; Jong Ik PARK ; Jungwoo SON ; Sung Man CHANG ; Bong Jin HAHM ; Jun Young LEE ; Jee Hoon SOHN ; Jin Sun KIM ; Jin Pyo HONG
Psychiatry Investigation 2015;12(2):164-170
OBJECTIVE: The aim of this study was to estimate the prevalence and correlates of mental disorders in Korean adults. METHODS: Door to door household surveys were conducted with community residents aged 18-74 years from July 19, 2011, to November 16, 2011 (n=6,022, response rate 78.7%). The sample was drawn from 12 catchment areas using a multistage cluster method. Each subject was assessed using the Korean version of the World Health Organization Composite International Diagnostic Interview (CIDI) based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). RESULTS: Lifetime and 12-month prevalence estimates were as follows: alcohol use disorders, 13.4% and 4.4%, respectively; nicotine use disorders, 7.2% and 4.0%, respectively; anxiety disorders, 8.7% and 6.8%, respectively; and mood disorders, 7.5% and 3.6%, respectively. The prevalence rates of all types of DSM-IV mental disorders were 27.6% and 16.0%, respectively. Being female; young; divorced, separated, or widowed; and in a low-income group were associated with mood and anxiety disorders after adjustment for various demographic variables, whereas being male and young were associated with alcohol use disorders. Higher income was not correlated with alcohol use disorder as it had been in the 2001 survey. CONCLUSION: The rate of depressive disorders has increased since 2001 (the first national survey), whereas that of anxiety disorders has been relatively stable. The prevalence of nicotine and alcohol use disorders has decreased, and the male-to-female ratio of those with this diagnosis has also decreased.
Adult*
;
Anxiety Disorders
;
Depressive Disorder
;
Diagnosis
;
Diagnostic and Statistical Manual of Mental Disorders*
;
Divorce
;
Family Characteristics
;
Female
;
Humans
;
Male
;
Mental Disorders*
;
Mood Disorders
;
Nicotine
;
Prevalence*
;
Tobacco Use Disorder
;
Widowhood
;
World Health Organization

Result Analysis
Print
Save
E-mail